Loading
Swapping bleomycin for the antibody-drug conjugate brentuximab vedotin in children's chemotherapy for advanced Hodgkin lymphoma cut the risk of relapse or death by 59 percent with no extra toxicity.
Open-label multicentre randomised phase 3 trial: 600 patients aged 2 to 21 with untreated high-risk classical Hodgkin lymphoma were assigned to five cycles of brentuximab vedotin with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide or to standard ABVE-PC, with PET-directed involved-site radiotherapy to slow-responding lesions.
At a median follow-up of 42.1 months three-year event-free survival was 92.1 percent with brentuximab vedotin against 82.5 percent with standard care (hazard ratio 0.41). Radiotherapy use (53.4 against 56.8 percent) and toxic effects were similar; three-year overall survival was 99.3 and 98.5 percent.
Brentuximab vedotin with AVEPC is the new standard for high-risk paediatric Hodgkin lymphoma and led to the first paediatric approval of the drug in November 2022.
Shares Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma.
Shares Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma.
Shares Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma.
Shares Brentuximab vedotin, Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Hodgkin lymphoma.
Shares Early-stage classical Hodgkin lymphoma (stage I to II), Hodgkin lymphoma, New England Journal of Medicine.
Shares Early-stage classical Hodgkin lymphoma (stage I to II), New England Journal of Medicine.
Shares Brentuximab vedotin, Early-stage classical Hodgkin lymphoma (stage I to II), Hodgkin lymphoma.
Shares Brentuximab vedotin, Hodgkin lymphoma.